Surfactant co-clathrates
    51.
    发明授权
    Surfactant co-clathrates 失效
    表面活性剂共包合物

    公开(公告)号:US6060522A

    公开(公告)日:2000-05-09

    申请号:US911123

    申请日:1997-08-14

    摘要: A solid, water-soluble complex comprising:a) a polysiloxane of the formula: ##STR1## wherein n is from 2 to 6; a is from 8 to 25; and b is from 0 to 25; and the oxyalkylene groups may be random or block mixtures; y is from 0 to 5; x is from 1 to 5; and R is selected from the group consisting of hydrogen, C.sub.1 -C.sub.4 alkyl, and a C.sub.1 -C.sub.4 alkyl ester; or ##STR2## wherein A is a linear or branched alkyl having 6 to 30 carbon atoms; G is a glycol moiety of the formula --R'(OCH.sub.2 CH.sub.2).sub.m OR" wherein R' is a divalent alkylene group having 2 to 6 carbon atoms; R" is selected from the group consisting of hydrogen, C.sub.1 -C.sub.4 alkyl, and a C.sub.1 -C.sub.4 alkyl ester; m is 8 to 100; y is 0 to 5; X is 0.1 to 2.5; and z is 0.1 to 5.0;b) a complex-forming agent of the formula: ##STR3## wherein X is O, S, Se, or Te, and c) a readily clathratable polyoxyethylene, e.g. a tridecyl alcohol ethoxylate having eight or more oxyethylene units.These complexes are useful as adjuvants for dry agricultural chemicals such as pesticides and/or fertilizers. The complex may also contain a non-clathratable polyoxyethylene, e.g. a block copolymer of ethylene oxide and propylene oxide having a ratio of ethylene oxide to propylene oxide of not more than about 0.87:1.

    摘要翻译: 一种固体水溶性络合物,其包含:a)下式的聚硅氧烷:其中n为2-6; a是8到25; b为0〜25; 氧化烯基可以是无规或嵌段混合物; y为0〜5; x为1〜5; 并且R选自氢,C 1 -C 4烷基和C 1 -C 4烷基酯; 或其中A是具有6至30个碳原子的直链或支链烷基; G是式-R'(OCH 2 CH 2)m OR“的二醇部分,其中R'是具有2至6个碳原子的二价亚烷基; R“选自氢,C 1 -C 4烷基和C 1 -C 4烷基酯; m为8〜100; y为0〜5; X为0.1〜2.5; z为0.1〜5.0; b)下式的络合物形成剂:其中X是O,S,Se或Te,和c)容易可熔化的聚氧乙烯,例如, 具有8个以上氧化乙烯单元的十三烷醇乙氧基化物。 这些复合物可用作干农药如农药和/或肥料的佐剂。 络合物还可以含有不可结合的聚氧乙烯,例如 具有环氧乙烷与环氧丙烷的比率的环氧乙烷和环氧丙烷的嵌段共聚物不大于约0.87:1。

    Process for preparing substituted urea derivatives
    53.
    发明授权
    Process for preparing substituted urea derivatives 失效
    制备取代脲衍生物的方法

    公开(公告)号:US4435567A

    公开(公告)日:1984-03-06

    申请号:US334470

    申请日:1981-12-28

    摘要: A process for the preparation of substituted urea derivatives, and compositions and concentrates for the same purpose are disclosed. According to the process the substituted urea derivatives of formula (I) ##STR1## wherein R is hydrogen, alkyl, aryl, cycloalkyl or aralkyl, R.sup.1 and R.sup.2 are hydrogen, alkyl, alkenyl, alkinyl, alkoxy, oxyalkyl, cycloalkyl, aralkyl, alkoxycarbonylalkyl, aryl or heteroaryl, or R.sup.1 and R.sup.2 together with the adjacent nitrogen atom may form a saturated or unsaturated heterocycle, or a condensed and/or substituted ring system, and said heterocycle or said condensed and/or substituted ring system may contain also a sulfo group,can be manufactured by reacting an amine of formula (II) ##STR2## with an N-carbamoyl-benzoic acid sulfimide derivative of formula (III) ##STR3## The disclosed N-acylating composition comprises of from 3 to 60% by weight, preferably of from 5 to 50% by weight sulfimide derivative of formula (III), of from 97 to 40% by weight, preferably of from 95 to 50% by weight solvent, and if desired, an organic or inorganic base.The disclosed N-acylating concentrate comprises of from 60 to 95.5% by weight N-acylating agent of formula (III) and of from 4.5 to 40% by weight additives.

    摘要翻译: 公开了用于制备取代的脲衍生物的方法,以及用于相同目的的组合物和浓缩物。 根据该方法,式(I)的取代脲衍生物其中R是氢,烷基,芳基,环烷基或芳烷基,R1和R2是氢,烷基,烯基,炔基,烷氧基,烷氧基,环烷基,芳烷基,烷氧基羰基 ,芳基或杂芳基,或R 1和R 2与相邻的氮原子一起可以形成饱和或不饱和的杂环或稠合和/或取代的环系,并且所述杂环或所述缩合和/或取代的环系可以含有磺基 可以通过使式(II)的胺与式(III)的N-氨基甲酰基 - 苯甲酸硫酰亚胺衍生物反应来制备。所公开的N-酰化组合物包含3至60重量% ,优选为5至50重量%的式(III)的亚磺酰亚胺衍生物,为97至40重量%,优选为95至50重量%的溶剂,如果需要,为有机或无机碱。 所公开的N-酰化浓缩物包含60至95.5重量%的式(III)的N-酰化剂和4.5至40重量%的添加剂。

    Process for integrated production of urea and urea-ammonium nitrate

    公开(公告)号:US10550075B2

    公开(公告)日:2020-02-04

    申请号:US16461719

    申请日:2017-09-04

    申请人: Casale SA

    发明人: Luca Rugnone

    摘要: Integrated process for the production of urea and urea-ammonium nitrate, comprising: reacting ammonia and carbon dioxide to form a reaction mixture (4) containing urea and unconverted materials, and also comprising the recovery of unconverted materials in a first recovery stage at a first pressure and in a second recovery stage at a second pressure, wherein ammonia-containing offgas (19) released by said second recovery stage are condensed at said second pressure, and said condensed offgas (20) are recycled to said first recovery stage.

    Tranilast compositions and cocrystals
    57.
    发明授权
    Tranilast compositions and cocrystals 有权
    T菜组合物和共晶体

    公开(公告)号:US09512064B2

    公开(公告)日:2016-12-06

    申请号:US14388948

    申请日:2013-03-29

    申请人: NUFORMIX LIMITED

    摘要: Mew tranilast complexes and new tranilast cocrystais are disclosed. These include all tranilast nicotinamide complex, a 1:1 tranilast nicotinamide cocrystal, a 1:1 tranilast saccharin complex, a 1:1 tranilast saccharin cocrystal, a 1:1 tranilast gentisic acid complex, a 1:1 tranilast gentisic acid cocrystal, a 1:1 tranilast salicylic acid complex, a 1:1 tranilast salicylic acid cocrystal, a 1:1 tranilast urea complex, a 1:1 tranilast urea cocrystal, a 1:1 tranilast 4-amtnoben2oic acid complex, a 1:1 tranilast 4-am!nobers2oic acid cocrystal, a 1:1 tranilast 2,4-di′hydroxybenzoic acid complex and a 1:1 tranilast 2,4-dihydroxybenzoic acid cocrystal. Also disclosed are pharmaceutical compositions containing a tranilast complex or cocrystal of the invention and a pharmaceutically acceptable carrier. Methods of treatment using the tranilast complexes and cocrystais as well as the pharmaceutical compositions are disclosed.

    摘要翻译: 披露了莫司利复合物和新的曲尼司特共晶体。 它们包括所有的曲尼司特烟酰胺复合物,1:1单螺旋烟酰胺共结晶体,1:1曲尼司特糖精配合物,1:1曲尼司特糖精共晶体,1:1曲尼司特龙胆酸复合物,1:1曲尼司特龙胆酸共晶体, 1:1曲尼司特水杨酸复合物,1:1曲尼司特水杨酸共晶体,1:1曲尼司特脲络合物,1:1曲尼司特尿素共结晶体,1:1曲尼司特4-氨基苯甲酸复合物,1:1曲尼司特4 -am!nobers2oic acid共结晶体,1:1曲尼司特2,4-二羟基苯甲酸复合物和1:1曲尼司特2,4-二羟基苯甲酸共晶体。 还公开了含有本发明的曲尼司特复合物或共结晶体和药学上可接受的载体的药物组合物。 公开了使用曲尼司特复合物和共晶的治疗方法以及药物组合物。

    Ionic liquids
    58.
    发明授权
    Ionic liquids 有权
    离子液体

    公开(公告)号:US09284264B2

    公开(公告)日:2016-03-15

    申请号:US13511179

    申请日:2010-11-25

    摘要: There is provided a mixture having a freezing point of up to 100° C. formed by a process comprising the step of contacting: (A) from 1 to 2 equivalents of a compound of formula (I) AlX3 (I) wherein each X independently represents Cl, Br or F; with (B) 1 equivalent of a compound of formula (II) R1—C(O)—N(R2)(R3) (II) wherein R1 to R3 have meanings given in the description. There is also provided further mixtures containing additional components, as well as methods of using the mixtures in various applications, such as for the electroreduction of the mixtures to produce aluminum metal.

    摘要翻译: 提供具有高达100℃的凝固点的混合物,其通过包括以下步骤的方法形成:(A)1至2当量的式(I)化合物AlX 3(I),其中每个X独立地 表示Cl,Br或F; 与(B)1当量的式(II)化合物R 1 -C(O)-N(R 2)(R 3)(II)其中R 1至R 3具有在说明书中给出的含义。 还提供了含有另外的组分的另外的混合物,以及在各种应用中使用混合物的方法,例如电解还原混合物以产生铝金属。

    TRANILAST COMPOSITIONS AND COCRYSTALS
    59.
    发明申请
    TRANILAST COMPOSITIONS AND COCRYSTALS 有权
    TRANILAST组合物和糖类

    公开(公告)号:US20150119428A1

    公开(公告)日:2015-04-30

    申请号:US14388948

    申请日:2013-03-29

    申请人: NUFORMIX LIMITED

    摘要: Mew tranilast complexes and new tranilast cocrystals are disclosed. These include all tranilast nicotinamide complex, a 1:1 tranilast nicotinamide cocrystal, a 1:1 tranilast saccharin complex, a 1:1 tranilast saccharin cocrystal, a 1:1 tranilast gentisic acid complex, a 1:1 tranilast gentisic acid cocrystal, a 1:1 tranilast salicylic acid complex, a 1:1 tranilast salicylic acid cocrystal, a 1:1 tranilast urea complex, a 1:1 tranilast urea cocrystal, a 1:1 tranilast 4-amtnoben2oic acid complex, a 1:1 tranilast 4-am!nobers2oic acid cocrystal, a 1:1 tranilast 2,4-di′hydroxybenzoic acid complex and a 1:1 tranilast 2,4-dihydroxybenzoic acid cocrystal. Also disclosed are pharmaceutical compositions containing a tranilast complex or cocrystal of the invention and a pharmaceutically acceptable carrier. Methods of treatment using the tranilast complexes and cocrystais as well as the pharmaceutical compositions are disclosed.

    摘要翻译: 公开了莫司利复合物和新的曲尼司特共晶体。 它们包括所有的曲尼司特烟酰胺复合物,1:1单螺旋烟酰胺共结晶体,1:1曲尼司特糖精配合物,1:1曲尼司特糖精共晶体,1:1曲尼司特龙胆酸复合物,1:1曲尼司特龙胆酸共晶体, 1:1曲尼司特水杨酸复合物,1:1曲尼司特水杨酸共晶体,1:1曲尼司特脲络合物,1:1曲尼司特尿素共结晶体,1:1曲尼司特4-氨基苯甲酸复合物,1:1曲尼司特4 -am!nobers2oic acid共结晶体,1:1曲尼司特2,4-二羟基苯甲酸复合物和1:1曲尼司特2,4-二羟基苯甲酸共晶体。 还公开了含有本发明的曲尼司特复合物或共结晶体和药学上可接受的载体的药物组合物。 公开了使用曲尼司特复合物和共晶的治疗方法以及药物组合物。

    ORAL SMOKELESS TOBACCO PRODUCTS AND ORAL SMOKELESS NON-TOBACCO SNUFF PRODUCTS COMPRISING CARBAMIDE OR CARBAMIDE SALTS
    60.
    发明申请
    ORAL SMOKELESS TOBACCO PRODUCTS AND ORAL SMOKELESS NON-TOBACCO SNUFF PRODUCTS COMPRISING CARBAMIDE OR CARBAMIDE SALTS 有权
    口服无烟烟草制品和口服无烟非烟草制品,包含碳水化合物或碳水化合物

    公开(公告)号:US20130053603A1

    公开(公告)日:2013-02-28

    申请号:US13579381

    申请日:2011-02-15

    IPC分类号: C07C275/02

    摘要: Oral smokeless tobacco products and oral smokeless non-tobacco snuff products include carbamide or carbamide salt(s). The carbamide salt is chosen from the group including carbamide calcium sulphate [4(CH4N2O).CaSO4], carbamide magnesium sulphate [6(CH4N2O).MgSO4.2H2O] and carbamide sodium chloride [CH4N2O).NaCl.H2O]. Moreover, carbamide or carbamide salt(s) are used in the manufacturing of oral smokeless tobacco products or oral smokeless non-tobacco snuff products.

    摘要翻译: 口服无烟烟草制品和口服无烟非烟草鼻烟制品包括尿素或尿酰胺盐。 硫脲酰胺盐选自硫酸钙[4(CH4N2O)·CaSO4],氨基硫酸镁[6(CH4N2O)·MgSO4·2H2O]和氨基甲酰胺氯化钠[CH4N2O]·NaCl·H2O2)。 此外,在制造口服无烟烟草制品或口服无烟非烟草鼻烟产品中使用尿素或尿酰胺盐。